Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 9Sarcoma 4Genitourinary 3Gastrointestinal 3Head & Neck 2Endocrine 2Dermatologic 2Breast 2Thoracic 1NET 1CNS 1

Conditions

Neuroendocrine Tumors 26Sarcoma 4Carcinoma, Neuroendocrine 4Prostatic Neoplasms 3Pheochromocytoma 3Paraganglioma 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Breast Neoplasms 3Adenoma, Islet Cell 3Thyroid Neoplasms 2Stomach Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Meningioma 2Melanoma 2Liver Neoplasms 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Digestive System Neoplasms 2Colonic Neoplasms 2Colonic Diseases 2Carcinoma, Renal Cell 2Carcinoid Tumor 2Adenocarcinoma 2

Interventions

tivozanib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vulvar Neoplasms × NET × 30 days × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡